Becton, Dickinson and Company's Stock Analysis

Becton Dickinson Announces Tender Offer Results and Pricing

Becton Dickinson and Company has announced the early tender results for its tender offers to purchase up to $2 billion of certain outstanding debt securities. The company has increased its Aggregate Offer Cap from $1.6 billion to $2 billion and amended the Offer SubCap for the 4.685% Senior Notes. As of the early tender date, a total of $36.5 million of the 6.700% Senior Notes, $32.8 million of the 7.000% Senior Debentures, and various amounts from other series of securities were tendered, exceeding the Aggregate Offer Cap, leading to a prorated acceptance for the 3.794% Senior Notes.

The company will make payments for the accepted securities on February 27, 2026, and holders of the validly tendered securities will also receive accrued interest. The tender offers are fully subscribed, and no additional purchases are expected after the early tender date. Investors are encouraged to refer to the Offer to Purchase for complete terms and conditions related to the tender offers.

Feb 25, 2026 16:25:34

Becton Dickinson Initiates $1.6 Billion Debt Tender Offers

Becton Dickinson and Company has announced the commencement of tender offers to purchase up to $1.6 billion in cash for various series of its outstanding debt securities. The offers include senior notes and debentures with different interest rates and maturity dates, and are subject to specific acceptance levels and purchase caps. The tender offers will expire on March 11, 2026, with an early tender date of February 24, 2026, for those wishing to receive additional consideration.

Investors interested in participating must validly tender their securities by the specified dates to receive the total consideration, which includes accrued interest. The company reserves the right to adjust the aggregate purchase price and other terms as necessary. Citigroup Global Markets Inc. and Wells Fargo Securities, LLC are the lead dealer managers for these offers, with further details available in the Offer to Purchase document provided to holders of the securities.

Feb 10, 2026 16:16:23

Becton Dickinson Completes Spin-Off and Merger with Waters Corporation

Becton Dickinson and Company has successfully completed the spin-off of its Biosciences and Diagnostic Solutions business, which has been combined with Waters Corporation. As part of the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock held as of February 5, 2026. BD also received a cash distribution of $4 billion from SpinCo, which it plans to allocate for share repurchases and debt repayment.

Following the merger, BD shareholders now own 39.2% of the outstanding shares of the combined company, valuing the spun-off business at $18.8 billion based on recent stock prices. Additionally, Claire M. Fraser has transitioned from the BD Board of Directors to join the Waters Board. The completion of these transactions is seen as a significant step in BD's strategic plan to focus on its core medical technology business.

Feb 09, 2026 16:18:11

Becton Dickinson Reports First Quarter Fiscal 2026 Results

Becton, Dickinson and Company announced its financial results for the first fiscal quarter ending December 31, 2025, reporting a revenue of $5.3 billion, which represents a 1.6% increase year-over-year. The company's GAAP diluted earnings per share (EPS) was $1.34, while the adjusted diluted EPS was $2.91. Additionally, the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close on the same day as the report, marking a significant strategic move for the company.

The company affirmed its fiscal year 2026 revenue growth guidance and provided adjusted diluted EPS guidance for the new BD. Key business highlights included collaborations to enhance hazardous drug testing, investments in U.S. pharmaceutical supply chains, and advancements in various medical technologies. The company also received FDA clearance for a new breast biopsy system and expanded its product offerings in Europe, indicating ongoing innovation and market expansion efforts.

Feb 09, 2026 06:31:33

Becton Dickinson Announces Spin-Off and Preferred Stock Issuance

Becton Dickinson and Company is preparing to distribute all outstanding shares of common stock of Augusta SpinCo Corporation, which will hold the company's Biosciences and Diagnostic Solutions business. This distribution is part of a Reverse Morris Trust transaction with Waters Corporation. The company has issued Series D Junior Participating Redeemable Preferred Stock in exchange for common stock held by certain trusts to prevent these trusts from receiving shares of SpinCo Common Stock during the distribution.

The Series D Preferred Shares are redeemable at the company's option for shares of common stock. If the distribution of SpinCo Common Stock is completed as planned, the Preferred Shares will be automatically redeemed for common stock at the specified redemption rate. The details of the Preferred Shares and their rights are outlined in the Certificate of Designation, which has been filed with the Secretary of State of New Jersey.

Feb 05, 2026 16:21:24

Becton Dickinson Restructures Business Segments Effective October 2025

Becton Dickinson and Company has reorganized its business structure into five distinct segments as of October 1, 2025. The new segments are BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. This reorganization aims to enhance the management of each segment, which develops and markets different products and services. The Life Sciences segment will be eliminated following the company's agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. Historical segment revenues for fiscal year 2025 have been recast to reflect this new structure.

Additionally, Becton Dickinson has provided investors with adjusted revenue figures and growth rates that exclude certain accruals related to past legal matters, which may affect comparability. The company emphasizes the importance of these non-GAAP measures to better understand performance trends and operational results. Investors are encouraged to review the consolidated financial statements in full, as these non-GAAP measures may differ from those used by other companies in the medical technology sector.

Feb 05, 2026 16:17:15

Becton Dickinson Approves Executive Severance Plan and Equity Amendment

Becton Dickinson and Company has established an Executive Severance Plan effective January 27, 2026, which provides severance benefits to designated management employees, including named executive officers, upon termination without cause. Benefits include a lump sum cash payment based on salary and target bonuses, pro-rated bonuses, and continued health benefits for eligible participants. The plan does not cover terminations for cause or voluntary resignations and requires compliance with certain conditions for payment.

Additionally, shareholders approved an amendment to the 2004 Employee and Director Equity-Based Compensation Plan, increasing the number of shares available for awards by 3,935,000 shares. During the 2026 Annual Meeting, all Board nominees were elected, and the appointment of Ernst & Young as the independent auditor for fiscal year 2026 was ratified. Shareholders also approved the compensation of named executive officers on an advisory basis.

Jan 30, 2026 16:17:28

Becton Dickinson Announces Blackout Period for 401(k) Plan

Becton, Dickinson and Company has announced that the BD 401(k) Plan will enter a blackout period due to a pending transaction with Waters Corporation. This blackout is necessary to incorporate the Waters Common Stock Fund into the Plan accounts and will commence after market close on the transaction's closing date, lasting until the week following that date.

During the blackout period, participants in the Plan will not be able to conduct any transactions involving the BD Common Stock Fund, including exchanges, loans, partial withdrawals, or final distributions. Shareholders and interested parties can obtain information about the blackout period's dates from Fidelity at a provided contact number, both during and for two years following the blackout period.

Jan 06, 2026 16:45:30

Becton Dickinson Elects Two New Board Members Effective December 2025

Becton Dickinson and Company announced the election of Robert L. Huffines and Jacqueline Wright to its Board of Directors, effective December 1, 2025. This election will increase the size of the Board from twelve to fourteen members. Both new members are considered independent according to New York Stock Exchange rules and will serve on various committees within the Board.

Upon their appointment, Huffines and Wright will receive prorated grants of restricted stock units, which will be disclosed in a future filing. Detailed compensation information for non-management Board members is available in the company's proxy statement for the 2025 Annual Meeting of Shareholders.

Nov 17, 2025 16:34:49

Becton Dickinson Reports Q4 and FY2025 Financial Results

Becton Dickinson and Company reported a fourth-quarter revenue of $5.9 billion, marking an 8.3% increase compared to the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $1.72 and an adjusted diluted EPS of $3.96. For the full fiscal year 2025, total revenue reached $21.8 billion, an 8.2% increase, while GAAP EPS slightly decreased to $5.82. Adjusted diluted EPS grew by 9.6% to $14.40, with gross margins improving in both GAAP and adjusted terms.

The company returned $2.2 billion to shareholders through dividends and share repurchases in FY25. Becton Dickinson also announced plans to complete the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation by early 2026. The company highlighted various business initiatives, including the launch of new AI-enabled solutions in its Medication Management Solutions unit and significant growth across its Urology and Critical Care segment. Additionally, it provided guidance for fiscal year 2026, indicating expectations for continued growth.

Nov 06, 2025 06:32:28